Antidepressants reduce phosphoinositide-specific phospholipase C (PI-PLC) activity and the mRNA and protein expression of selective PLC β1 isozyme in rat brain

Neuropharmacology

Volumn 43, Issue 8, 2002, Pages 1269-1279

  Dwivedi, Y ^a   Agrawal, A K ^a   Rizavi, H S ^a   Pandey, G N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antidepressants; mRNA; Phospholipase C; Rat brain

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; DESIPRAMINE; FLUOXETINE; ISOENZYME; MESSENGER RNA; METACHLOROPHENYLPIPERAZINE; PHENELZINE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHOLIPASE C; PIPERAZINE DERIVATIVE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BRAIN CORTEX; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; ENZYME ACTIVITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; MALE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHOLIPASE C; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 0036951287     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00253-8     Document Type: Article

References (67)

1. 2+ ion concentrations. Biochemical Journal. 327:1997;545-552.
2. Baker G.B., Greenshaw A.J. Effects of subchronic administration of antidepressants on receptors in central nervous system. Cellular and Molecular Neurobiology. 9:1989;1-44.
3. Berridge M.J., Irvine R.F. Inositol phosphates and cell signaling. Nature. 341:1989;197-205.
4. Blier P., de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biological Psychiatry. 44:1998;313-323.
5. 2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperezine (mCPP). The European Journal of Pharmacology. 257:1994;27-38.
6. s) and adenylyl cyclase. Journal of Neurochemistry. 64:1995;724-732.
7. Cimino M., Ponzio F., Achilli G., Vantini G., Perego C., Algeri S., Garattini S. Dopaminergic effects of buspirone and gepirone. Biochemical Pharmacology. 32:1983;1069-1074.
8. Dwivedi Y., Pandey S.C., Ren X., Tueting P., Pandey G.N. Effect of desipramine, lithium, and adinazolam on serotonin receptor subtypes in rat brain. Society of Neuroscience Abstract. 20:1994;1161.
9. Dwivedi Y., Pandey G.N. Effects of subchronic administration of antidepressants and anxiolytics on levels of the α subunits of G proteins in the rat brain. Journal of Neural Transmission. 104:1997;747-760.
10. Dwivedi Y., Rizavi H.S., Rao J.S., Pandey G.N. Modifications in the phosphoinositide signaling pathway by adrenal glucocorticoids in rat brain: Focus on phosphoinositide-specific phospholipase C and inositol 1, 4, 5-trisphosphate. The Journal of Pharmacology and Experimental Therapeutics. 295:2000;244-254.
11. Dyck L.E., Boulton A.A. Effects of antidepressant drugs on inositol phospholipid hydrolysis in rat cerebral cortical slices. Biological Research. 14:1989;1047-1052.
12. Fuxe K., Ogren S., Agnati L.F., Anderson K., Eneroth P. On the mechanism of action of antidepressant drugs: Indication of reduction in 5-HT neurotransmission in some brain regions upon subchronic treatment. Langer S.Z., Takahashi R., Segawa T., Briely M. New Vistas in Depression. 1982;49 Pergamon Press, New York.
13. Gommans J., Hijzen T.H., Maes R.A., Olivier B. Discriminative stimulus properties of alprazolam. Psychopharmacology (Berl). 148:2000;146-152.
14. Goodnough D.B., Baker G.B. 5-hydroxytryptamine 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. Journal of Neurochemistry. 62:1994;2262-2268.
15. Giusti P., Guidotti A., Costa E. The anticonflict (AC) and antiproconflict (AP) effect of alprazolam (ALZ), clonazepam (CLZ) and bretazenil (BTZ) due to their preferential binding to specific GABA-A receptor subtypes. Neuroscience Letters. 39:1990;S109.
16. Griebel G., Misslin R., Pawlowski M., Vogel E. m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. Neuroreport. 2:1991;627-629.
17. Heninger G.R., Charney D.S. Mechanism of action of antidepressant treatments: Implications for the etiology and treatment of depressive disorders. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;535-544 Raven Press, New York.
18. Hintgen J.N., Hendrie H.C., Aprison M.H. Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression. Pharmacology Biochemistry Behavior. 20:1984;425-428.
19. Hrdina P.D., Vu T.B. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: An autoradiographic study. Synapse. 14:1993;324-331.
20. Karege F., Bovier P., Waltraut R., Gaillard J.M. Platelet phosphoinositide signaling system: An over-stimulated pathway in depression. Biological Psychiatry. 39:1996;697-702.
21. Keller K.J., Cascio C.S., Butler J.A., Kurtzke R.N. Differential effects of electroconvulsive shock and antidepressant drugs on serotonin-2-receptors in rat brain. The European Journal of Pharmacology. 69:1981;515-518.
22. Kendall D.A., Nahorski S.R. 5-hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: Pharmacological characterization and effects of antidepressants. The Journal of Pharmacology and Experimental Therapeutics. 233:1985;473-479.
23. Kennett G.A., Whitton P., Shah K., Curzon G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. European Journal of Pharmacology. 164:1989;445-454.
24. Lowry O.H., Roseburg N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. Journal of Biochemistry. 193:1951;265-275.
25. Lucki I. The nonbenzodiazepine anxiolytics buspirone and ipsapirone antagonize serotonin-mediated behavioral responses. Psychopharmacology. 89:1986;S55.
26. Manji H.D. G proteins: Implications for psychiatry. American Journal of Psychiatry. 149:1992;746-760.
27. Mann C.D., Bich V.T., Hrdina P.D. Protein kinase C in rat brain cortex and hippocampus: Effects of repeated administration of fluoxetine and desipramine. British Journal of Pharmacology. 115:1995;595-600.
28. Marek G.J., McDougle C.J., Price L.H., Seiden L.S. A comparison of trazodone and fluoxetine: Implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1091:1992;2-11.
29. 2-adrenoceptor function. Journal of Pharmaceutical Sciences. 81:1992;832-835.
30. McMillen B.A., McDonald C.C. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. Neuropharmacology. 22:1983;273-278.
31. Mikuni M., Kusumi I., Kagaya A., Mori H., Takahashi K. Increased 5-HT-2 receptor function as measured by serotonin-stimulated phosphoinositide hydrolysis in platelets of depressed patients. Progress in Neuropsychopharmacol and Biological Psychiatry. 1991;1549-1561.
32. Mori H., Koyama T., Yamashita I. Platelet alpha-2 adrenergic receptor-mediated phosphoinositide responses in endogenous depression. Life Science. 48:1991;741-748.
33. Murthy S.N., Lomasney J.W., Mak E.C., Lorand L. Interactions of Gh/transglutaminase with PLC-delta1 and with GTP. Proceedings of the National Academy of Sciences of the United States of America. 96:1999;11815-11819.
34. Nelson J.C., Davis J.M. DST studies in psychotic depression: A meta-analysis. Am. J. Psychiatry. 154:(11):1997;1497-1503.
35. Neumaier J.F., Root D.C., Hamblin M.W. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology. 15:1996;515-522.
36. Okada F., Tokumitsu Y., Ui M. Possible involvement of pertussis toxin substrates (Gi, Go) in desipramine-induced refractoriness of adenylate cyclase in cerebral cortices of rats. Journal of Neurochemistry. 51:1988;194-199.
37. 1-adrenoceptors in the amygdala of rat after antidepresssant treatments. Journal of Pharmacology and Experimental Therapeutics. 257:1991;681-690.
38. Osborne N.N. Tricyclic antidepressants mianserin and ouabain stimulate inositol phosphate formation in vitro in rat cortical slices. Neurochemistry Research. 13:1988;105-111.
39. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics. 283:1997;1305-1322.
40. s to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. Journal of Neurochemistry. 56:1991;330-338.
41. Pacher P., Kohegyi E., Kecskemeti V., Furst S. Current trends in the development of new antidepressants. Current Medical Chemistry. 8:2001;89-100.
42. Paetsch P.R., Greenshaw A.J. Effects of chronic antidepressant treatment on beta-adrenoceptor subtype binding in the rat cerebral cortex and cerebellum. Molecular and Chemical Neuropathology. 20:1993;21-31.
43. Pandey G.N., Pandey S.C., Davis J.M. Effect of desipramine on inositol phosphate formation and inositol phospholipids in rat brain and human platelets. Psychopharmacol Bulletin. 27:1991;255-261.
44. Pandey G.N., Ren X., Pandey S.C., Dwivedi Y., Sharma R., Janicak P.G. Hyperactive phosphoinositide signaling pathway in platelets of depressed patients: Effect of desipramine treatment. Psychiatry Research. 105:2001;23-32.
45. Pandey G.N., Sudershan P., Davis J.M. Beta adrenergic receptor function in depression and the effect of antidepressant drugs. Acta Pharmacolgy Toxicology. 56:(Suppl 1):1985;66-79.
46. Pandey, S.C., Dwivedi, Y., Pandey, G.N., 1993. Effect of treatment with mCPP and alprazolam on serotonin receptor subtypes and phosphoinositide signaling system. 32nd Annual Meeting of American College of Neuropharmacology, p. 167.
47. Petroutka S.J. Selective interaction of novel anxiolytics with 5-hydroxytryptamine-1A receptors. Biological Psychiatry. 20:1985;971-979.
48. Petroutka S.J., Snyder S.H. Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science. 210:1990;88-90.
49. Popoli M., Brunello N., Perez J., Racagni G. Second messenger-regulated protein kinases in the brain: Their functional role and the action of antidepressant drugs. Journal of Neurochemistry. 74:2000;21-33.
50. Popoli M., Mori S., Brunello N., Perez J., Gennarelli M., Racagni G. Serine/threonine kinases as molecular targets of antidepressants: Implications for pharmacological treatment and pathophysiology of affective disorders. Pharmacology and Therapeutics. 8:2001;149-170.
51. Rebecchi M.J., Pentyala S.N. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiological Reviews. 80:2000;1291-1335.
52. Rhee G.S. Regulation of phosphoinositide-specific phospholipase C. Annual Review of Biochemistry. 70:2001;281-312.
53. Sanders-Bush E., Breeding M., Knoth K., Tsutumi M. Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. Psychopharmacology. 99:1989;64-69.
54. Schmidt M.J., Fuller R.W., Wong D.T. Fluoxetine, a highly selective serotonin reuptake inhibitor: A review of preclinical studies. The British Journal of Psychiatry. 153:1988;40-46.
55. 2 and β-adrenoreceptors in different reports of rat brain. Neuroscience. 8:1983;161-164.
56. 2 receptor sites and inositoltrisphosphate levels in rat brain. Neurochemical Research. 22:1997;1095-1099.
57. Suh P.G., Ryu S.H., Choi W.C., Lee K.Y., Rhee S.G. Monoclonal antibodies to three phospholipase C isozymes from bovine brain. Journal of Biological Chemistry. 263:1988;14497-14504.
58. Sulser F. New perspectives on the mode of action of antidepressant drugs. Trends of Pharmacological Sciences. 1:1979;92.
59. Taylor D.P. Serotonin agents in anxiety. Annals of the New York Academy of Sciences. 600:1990;556-557.
60. 2A receptors without affecting benzodiazepine binding sites in rat brain. Cell and Molecular Neurobiology. 15:1995;361-370.
61. Trouvin J.H., Gardier A.M., Chanut E., Pages N., Jacquot C. Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat. Life Science. 52:1993;187-192.
62. Ulrichsen J., Partilla J.S., Dax E.M. Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion. Psychopharmacology. 107:1992;229-235.
63. Vetulani J., Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature. 257:1975;495-496.
64. Vetulani J. The development of our understanding of the mechanism of action of antidepressant drugs. Polish Journal of Pharmacology and Pharmacy. 43:1991;323-338.
65. Wong D.T., Reid L.R., Bymaster F.P., Threlkeld P.G. Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmiter receptors. Journal of Neural Transmission. 64:1985;251-269.
66. Yocca F.D., Hyslop D.K., Taylor D.P., Maayani S. Buspirone and gepirone: Partial agonists at the 5-HT-1A receptor linked to adenylate cyclase (AC) in the rat and guinea pig hippocampal preparations. Federation Proceedings. 45:1986;436.
67. Zuardi A.W. 5-HT-related drugs and human experimental anxiety. Neuroscience and Biobehavioral Reviews. 14:1990;507-510.